More to come from PARP drugs, says biotech CEO after striking radiotherapy deal with AZ

Five years AstraZeneca became an oncology trailblazer by getting the first PARP inhibitor class drug Lynparza, approved by the FDA for certain ovarian cancers.

Now the UK pharma is aiming to build on this by striking a licence arrangement with UK biotech Theragnostics to develop based on poly (ADP-ribose) polymerase (PARP) inhibitors attached to a radioactive atom that could be used to both image cancer and treat it.